JP2024532886A - ヒトＣＤ１６ａに対する抗体及びその変異体 - Google Patents

ヒトＣＤ１６ａに対する抗体及びその変異体 Download PDF

Info

Publication number
JP2024532886A
JP2024532886A JP2024512952A JP2024512952A JP2024532886A JP 2024532886 A JP2024532886 A JP 2024532886A JP 2024512952 A JP2024512952 A JP 2024512952A JP 2024512952 A JP2024512952 A JP 2024512952A JP 2024532886 A JP2024532886 A JP 2024532886A
Authority
JP
Japan
Prior art keywords
seq
antibody
antigen
binding portion
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024512952A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024532886A5 (enExample
Inventor
カン、リウ
ヂョンダオ、リ
ヂィーフェイ、ザオ
クイイェン、シャオ
ビン、リウ
イ、ジン
リウソン、イン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Jinsirui Science and Technology Biology Corp
Original Assignee
Nanjing Jinsirui Science and Technology Biology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Jinsirui Science and Technology Biology Corp filed Critical Nanjing Jinsirui Science and Technology Biology Corp
Publication of JP2024532886A publication Critical patent/JP2024532886A/ja
Publication of JP2024532886A5 publication Critical patent/JP2024532886A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2024512952A 2021-08-25 2022-08-25 ヒトＣＤ１６ａに対する抗体及びその変異体 Pending JP2024532886A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/114549 2021-08-25
CN2021114549 2021-08-25
PCT/CN2022/114642 WO2023025215A1 (en) 2021-08-25 2022-08-25 ANTIBODIES AND VARIANTS THEREOF AGAINST HUMAN CD16a

Publications (2)

Publication Number Publication Date
JP2024532886A true JP2024532886A (ja) 2024-09-10
JP2024532886A5 JP2024532886A5 (enExample) 2025-09-01

Family

ID=85321557

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024512952A Pending JP2024532886A (ja) 2021-08-25 2022-08-25 ヒトＣＤ１６ａに対する抗体及びその変異体

Country Status (6)

Country Link
US (1) US20240352128A1 (enExample)
EP (1) EP4392453A4 (enExample)
JP (1) JP2024532886A (enExample)
KR (1) KR20240049331A (enExample)
CN (1) CN117858902A (enExample)
WO (1) WO2023025215A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4676965A1 (en) * 2023-03-03 2026-01-14 Beone Medicines I GmbH Cd16a antibodies and methods of use
EP4676975A1 (en) * 2023-03-03 2026-01-14 Beone Medicines I GmbH Muc1 and cd16a antibodies and methods of use
WO2024206126A1 (en) * 2023-03-27 2024-10-03 Modernatx, Inc. Cd16-binding antibodies and uses thereof
CN120025439B (zh) * 2023-11-21 2026-04-17 南京融捷康生物科技有限公司 一种抗CD16a的单域抗体及其用途
CN118221818B (zh) * 2024-04-29 2025-01-24 四川大学 一种抗cd16a的纳米抗体及其应用
CN121758624A (zh) * 2024-09-23 2026-03-31 北京智仁美博生物科技有限公司 结合人cd16和/或人cd123的多种抗体及其用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005532342A (ja) * 2002-05-30 2005-10-27 マクロジェニクス，インコーポレーテッド Ｃｄ１６ａ結合タンパク質および免疫障害治療のための使用
JP2008541714A (ja) * 2005-05-26 2008-11-27 アフィメート テラポイティクス アーゲー 抗ｃｄ１６結合分子
JP2009500458A (ja) * 2005-07-11 2009-01-08 マクロジェニクス，インコーポレーテッド ヒト化抗ｃｄ１６ａ抗体を用いる自己免疫疾患の治療方法
WO2018039626A1 (en) * 2016-08-25 2018-03-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human single domain antibodies targeting cd16a to mediate adcc
JP2020510657A (ja) * 2017-02-28 2020-04-09 アッフィメッド・ゲー・エム・ベー・ハーＡｆｆｉｍｅｄ Ｇｍｂｈ 抗ｃｄ１６ａ抗体のサイトカインとの組み合わせ

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
US20240101677A1 (en) * 2021-01-27 2024-03-28 Innovent Biologics (Suzhou) Co., Ltd. Single-domain antibody against cd16a and use thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005532342A (ja) * 2002-05-30 2005-10-27 マクロジェニクス，インコーポレーテッド Ｃｄ１６ａ結合タンパク質および免疫障害治療のための使用
JP2008541714A (ja) * 2005-05-26 2008-11-27 アフィメート テラポイティクス アーゲー 抗ｃｄ１６結合分子
JP2009500458A (ja) * 2005-07-11 2009-01-08 マクロジェニクス，インコーポレーテッド ヒト化抗ｃｄ１６ａ抗体を用いる自己免疫疾患の治療方法
WO2018039626A1 (en) * 2016-08-25 2018-03-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human single domain antibodies targeting cd16a to mediate adcc
JP2020510657A (ja) * 2017-02-28 2020-04-09 アッフィメッド・ゲー・エム・ベー・ハーＡｆｆｉｍｅｄ Ｇｍｂｈ 抗ｃｄ１６ａ抗体のサイトカインとの組み合わせ

Also Published As

Publication number Publication date
KR20240049331A (ko) 2024-04-16
US20240352128A1 (en) 2024-10-24
EP4392453A1 (en) 2024-07-03
EP4392453A4 (en) 2025-10-08
WO2023025215A1 (en) 2023-03-02
CN117858902A (zh) 2024-04-09

Similar Documents

Publication Publication Date Title
US20260078166A1 (en) Anti-dll3 chimeric antigen receptors and uses thereof
AU2019243665B2 (en) Multivalent antibody
US20240352128A1 (en) ANTIBODIES AND VARIANTS THEREOF AGAINST HUMAN CD16a
AU2019326635B2 (en) Anti-PD-L1/anti-LAG3 bispecific antibodies and uses thereof
JP2023051968A (ja) 多重特異的ＮＫｐ４６結合タンパク質
WO2022068854A1 (en) Antibodies targeting human claudin 18.2 and uses thereof
JP2009529920A (ja) Ｒａｇｅの拮抗作用のための方法および組成物
TW202340248A (zh) 促效性ｌｔｂｒ抗體及包含其之雙特異性抗體
JP2021522347A (ja) Ｐｄ−１およびｌａｇ−３に対する高親和性抗体ならびにそれらから作製された二重特異性結合タンパク質
CN113527493B (zh) 一种b7-h3抗体及其应用
CN120424213A (zh) 特异性结合pd-1的单克隆抗体及其医药用途
WO2025077834A1 (en) Anti-il-4ra antibodies and uses thereof
WO2025255558A2 (en) Anti-thymic stromal lymphopoietin (tslp) antigen-binding proteins and uses thereof
TW202214705A (zh) 抗tigit抗體及雙抗體和它們的應用
KR20260016889A (ko) B7-h3을 표적하는 항체, 및 이를 포함하는 키메라 항원 수용체
HK40065826A (en) Anti-dll3 chimeric antigen receptors and uses thereof
HK40098926A (en) Anti-dll3 chimeric antigen receptors and uses thereof
CA3161390A1 (en) Antibodies binding to hla-a2/mage-a4
CN116888156A (zh) 非阻断性人ccr8结合剂
HK40065826B (en) Anti-dll3 chimeric antigen receptors and uses thereof
WO2026052652A1 (en) Cytokine receptor agonist
HK40044020A (en) High affinity antibodies to pd-1 and lag-3 and bispecific binding proteins made therefrom

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250821

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250821

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260526